LIFECELL CORP
10-Q, EX-27.1, 2000-07-31
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: LIFECELL CORP, 10-Q, EX-10.3, 2000-07-31
Next: FIRST TRUST COMBINED SERIES 80, 485BPOS, 2000-07-31



<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1

<S>                                     <C>
<PERIOD-TYPE>                           6-MOS
<FISCAL-YEAR-END>                       DEC-30-2000
<PERIOD-START>                          JAN-01-2000
<PERIOD-END>                            JUN-30-2000
<CASH>                                   1,218,885
<SECURITIES>                               315,244
<RECEIVABLES>                            5,087,722
<ALLOWANCES>                              (206,540)
<INVENTORY>                              3,843,257
<CURRENT-ASSETS>                        10,555,019
<PP&E>                                  11,809,185
<DEPRECIATION>                          (2,139,922)
<TOTAL-ASSETS>                          20,888,071
<CURRENT-LIABILITIES>                    9,358,640
<BONDS>                                          0
                            0
                                     93
<COMMON>                                     14183
<OTHER-SE>                                 862,349
<TOTAL-LIABILITY-AND-EQUITY>            20,888,071
<SALES>                                  9,825,170
<TOTAL-REVENUES>                        10,678,635
<CGS>                                    3,100,351
<TOTAL-COSTS>                             13752950
<OTHER-EXPENSES>                                 0
<LOSS-PROVISION>                                 0
<INTEREST-EXPENSE>                         360,699
<INCOME-PRETAX>                         (3,305,121)
<INCOME-TAX>                                     0
<INCOME-CONTINUING>                     (3,305,121)
<DISCONTINUED>                                   0
<EXTRAORDINARY>                                  0
<CHANGES>                                        0
<NET-INCOME>                            (3,305,121)
<EPS-BASIC>                                 (.26)
<EPS-DILUTED>                                 (.26)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission